Research Papers

Development of an Oral Curcumin Nanocrystal Formulation

[+] Author and Article Information
R. Ravichandran

Regional Institute of Education (NCERT),
Mysore 570006, India
e-mail: ravincert@gmail.com

Manuscript received August 8, 2012; final manuscript received February 25, 2013; published online April 16, 2013. Assoc. Editor: Roger Narayan.

J. Nanotechnol. Eng. Med 3(4), 041007 (Apr 16, 2013) (7 pages) doi:10.1115/1.4023947 History: Received August 08, 2012; Revised February 25, 2013

During the last ten years, the formulation of drugs as nanocrystals has rapidly evolved into a mature drug delivery strategy, with currently five products on the market. The major characteristic of these systems is the rapid dissolution velocity, enabling bioavailability enhancement after oral administration. This study describes the preparation of a solid dosage capsule form of spray-dried curcumin nanocrystal and compares its dissolution behavior with market capsule in different media. The aim was to obtain a stable nanocrystal loaded drug capsule with an increased drug saturation solubility and dissolution velocity. The solubility and dissolution experiments were performed to verify the obvious improvement of the dissolution behavior compared with commercial product. Improved dissolution behavior in drug nanocrystal-loaded solid dosage forms should lead to better bioavailability of poorly soluble drugs in the body.

Copyright © 2013 by ASME
Topics: Nanocrystals , Drugs
Your Session has timed out. Please sign back in to continue.


Shishodia, S., Sethi, G., and Aggarwal, B. B., 2005, “Curcumin: Getting Back to the Roots,” Ann. N.Y. Acad. Sci., 1056, pp. 206–217. [CrossRef] [PubMed]
Chattopadhyay, K., Biswas, U., Bandyopadhyay, and Banerjee, R. K., 2004, “Turmeric and Curcumin: Biological Actions and Medicinal Applications,” Curr. Sci., 87, pp. 44–53. Available at http://goldenmilk.net/pdfs/Curcumin_Medicinal_Appications_Chattopadhyay_etal.pdf
Duke, J. A., 2002, CRC Handbook of Medicinal Spices, CRC Press, Boca Raton, FL, pp. 137–144.
Ammon, H. P. T., and Wahl, M. A., 1991, “Pharmacology of Curcumin,” Planta Med., 57, pp. 1–7. [CrossRef] [PubMed]
Aggarwal, B. B., Sundaram, C., Malani, N., and Ichikawa, H., 2007, “Curcumin: The Indian Solid Gold,” The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease (Advances in Experimental Medicine and Biology), Vol. 595, Springer, New York, pp. 1–75. [CrossRef]
Hatcher, H., Planalp, R., Cho, J., Torti, F. M., and Torti, S. V., 2008, “Curcumin: From Ancient Medicine to Current Clinical Trials,” Cell. Mol. Life Sci., 65(11), pp. 1631–1652. [CrossRef] [PubMed]
Joe, B., Vijaykumar, M., and Lokesh, B. R., 2004, “Biological Properties of Curcumin-Cellular and Molecular Mechanisms of Action,” Crit. Rev. Food Sci. Nutr., 44, pp. 97–111. [CrossRef] [PubMed]
Mancuso, C., and Barone, E., 2009, “Curcumin in Clinical Practice: Myth or Reality?,” Trends Pharm. Sci., 30(7), pp. 333–334. [CrossRef]
Maheshwari, R. K., Singh, A. K., Gaddipati, J., and Srimal, R. C., 2006, “Multiple Biological Activities of Curcumin: A Short Review,” Life Sci., 78, pp. 2081–2087. [CrossRef] [PubMed]
Duvoix, A., Blasius, R., Delhalle, S., Schnekenburger, M., Morceau, F., Henry, E., Dicato, M., and Diederich, M., 2005, “Chemopreventive and Therapeutic Effects of Curcumin,” Cancer Lett., 223, pp. 181–190. [CrossRef] [PubMed]
Tonnesen, H. H., and Karlsen, J., 1985, “Studies of Curcumin and Curcuminoids: V. Alkaline Degradation of Curcumin,” Z. Lebensm. Unters. Forsch., 180, pp. 132–134. [CrossRef]
Anand, P., Kunnumakkara, A. B., Newman, R. A., and Aggarwal, B. B., 2007, “Bioavailability of Curcumin: Problems and Promises,” Mol. Pharm., 4(6), pp. 807–818. [CrossRef] [PubMed]
Bansal, A. K., Munjal, B., and Patel, S., 2009, “Novel Self-Emulsifying Curcumin Compositions With Enhanced Bioavailability,” PCT Filed 2 April 2009, No. PCT/IB/2009/005154.
Bansal, A. K., Munjal, B., and Patel, S., 2008, “Novel Self Nano Emulsifying Curcumin (Curcuminoids) Composition With Enhanced Bioavailability,” Indian Patent Application Filed 24 July 2008, No. 1776/DEL/2008.
Lao, C. D., Ruffin, M. T., Normolle, D., Heath, D. D., Murray, S.I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., and Brenner, D. E., 2006, “Dose Escalation of a Curcuminoid Formulation,” BMC Compl. Altern. Med., 6, p. 10. [CrossRef]
Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., and Srinivas, P. S., 1998, “Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers,” Planta Med., 64, pp. 353–356. [CrossRef] [PubMed]
Li, L., Braiteh, F. S., and Kurzrock, R., 2005, “Liposome-Encapsulated Curcumin: In Vitro and In Vivo Effects on Proliferation, Apoptosis, Signaling, and Angiogenesis,” Cancer, 104, pp. 1322–1331. [CrossRef] [PubMed]
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., and Maitra, A., 2007, “Polymeric Nanoparticle-Encapsulated Curcumin (‘Nanocurcumin’): A Novel Strategy for Human Cancer Therapy,” J. Nanobiotechn. (BioMed Central), 5(3), p. 3. [CrossRef]
Liu, A., Lou, H., Zhao, L., and Fan, P., 2006, “Validated LC/MS/MS Assay for Curcumin and Tetrahydrocurcumin in Rat Plasma and Application to Pharmacokinetic Study of Phospholipids Complex of Curcumin,” J. Pharm. Biomed. Anal., 40, pp. 720–727. [CrossRef] [PubMed]
Thomas, S. L., Zhong, D., Zhou, W., Malik, S. W., Liotta, D., Snyder, J. P., Hamel, E., and Giannakakou, P., 2008, “EF24, a Novel Curcumin Analog, Disrupts the Microtubule Cytoskeleton and Inhibits HIF-1,” Cell Cycle, 7(15), pp. 2409–2417.
Hatcher, H., Planalp, R., Cho, J., Torti, F. M., and Torti, S. V., 2008, “Curcumin: From Ancient Medicine to Current Clinical Trials,” J. Cell. Mol. Life Sci., 65(11), pp. 1631–1652. [CrossRef]
Ravichandran, R., 2009, “Nanoparticles in Drug Delivery: Potential Green Nanobiomedicine Applications,” Int. J. Green Nanotech. Biomed., 1(2), pp. B108–B130 [CrossRef].
Ravichandran, R., 2010, “Nanotechnology-Based Drug Delivery Systems,” NanoBiotechnology, 5(1), pp. 17–33 [CrossRef]
Chen, X., Young, T. J., Sarkari, M., Williams, R. O., and Johnston, K. P., 2002, “Preparation of Cyclosporine a Nanoparticles by Evaporative Precipitation Into Aqueous Solution,” Int. J. Pharm., 242, pp. 3–14. [CrossRef] [PubMed]
Muller, R. H., Jacobs, C., and Kayser, O., 2001, “Nanosuspensions as Particulate Drug Formulations in Therapy: Rationale for Development and What We Can Expect for the Future,” Adv. Drug Del. Rev., 47, pp. 3–19. [CrossRef]
Weder, H. G., and van Hoogevest, P., 1998, “Nanosuspensions for Intravenous Administration,” U.S. Patent No. 5726164.
Muller, R. H., and Jacobs, C., 2002, “Buparvaquone Mucoadhesive Nanosuspensions: Preparation, Optimisation and Long-Term Stability,” Int. J. Pharm., 237, pp. 151–161. [CrossRef] [PubMed]
Rabinow, B. E., 2004, “Nanosuspensions in Drug Delivery,” Nat. Rev. Drug Discov., 3, pp. 785–796. [CrossRef] [PubMed]
Keck, C. M., and Muller, R. H., 2006, “Drug Nanocrystals of Poorly Soluble Drugs Produced by High Pressure Homogenization,” Eur. J. Pharm. Biopharm., 62(1), pp. 3–16. [CrossRef] [PubMed]
Liversidge, G. G., and Cundy, K. C., 1995, “Particle Size Reduction for Improvement of Oral Bioavailability of Hydrophobic Drugs: I. Absolute Oral Bioavailability of Nanocrystalline Danazol in Beagle Dogs,” Int. J. Pharm., 125, pp. 91–97. [CrossRef]
Jinno, J., Naoki, K., Miyake, M., Yamada, K., Mukia, T., Odomi, M., Togu-chi, H., Liversidge, G. G., Higaki, K., and Kimura, T., 2006, “Effect of Particle Size Reduction on Dissolution and Oral Absorption of a Poorly Water-Soluble Drug, Cilostazol, in Beagle Dogs,” J. Control. Release, 111, pp. 56–64. [CrossRef] [PubMed]
Liversidge, G. G., and Conzentino, P., 1995, “Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats,” Int. J. Pharm., 125, pp. 309–313. [CrossRef]
Gao, L., Zhang, D., and Chen, M., 2008, “Drug Nanocrystals for the Formulation of Poorly Soluble Drugs and Its Application as a Potential Drug Delivery System,” J. Nanoparticle Res., 10(5), pp. 845–862. [CrossRef]
Ravichandran, R., 2010, “Preparation and Characterisation of Curcumin Nanosuspension for Enhanced Solubility and Dissolution Velocity,” Int. J. Nano Biomater., 3(2), pp. 153–186. [CrossRef]
Donsì, F., Wang, Y., Li, J., and Huang, Q., 2010, “Preparation of Curcumin Sub-Micrometer Dispersions by High-Pressure Homogenization,” J. Agric. Food Chem., 58(5), pp. 2848–2853. [CrossRef]
Noyes, A. A., and Whitney, W. R., 1897, “The Rate of Solution of Solid Substances in Their Own Solutions,” J. Am. Chem. Soc., 19, pp. 930–934. [CrossRef]
Muller, R. H., Jacobs, C., and Kayser, O., 2000, “Nanosuspensions for the Formulation of Poorly Soluble Drugs,” Pharmaceutical Emulsions and Suspensions, F.Nielloudand, and G.Marti-Mestres, eds., Marcel Dekker, New York, pp. 383–407.
Muller, R. H., and Akkar, A., 2004, “Drug Nanocrystals of Poorly Soluble Drugs,” Encyclopedia of Nanoscience and Nanotechnology, H. S.Nalwa, ed., American Scientific, Los Angeles, CA, pp. 627–638.
Takano, R., Furumoto, K., Shiraki, K., Takata, N., Hayashi, Y., Aso, Y., and Yamashita, S., 2008, “Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction From a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation,” Pharm. Res., 25(10), pp. 2334–2344. [CrossRef] [PubMed]
Hintz, R. J., and Johnson, K. C., 1989, “The Effect of Particle Size Distribution on Dissolution Rate and Oral Absorption,” Int. J. Pharm., 51, pp. 9–17. [CrossRef]
Keck, C., Fichtinger, A., Viernstein, H., and Muller, R. H., 2004, “Oral Drug Nanocrystals—Effect of Potential Aggregation on Bioavailability,” Annual Meeting of Pharmaceutical Scientists (AAPS), Baltimore, MD, p. 2746.


Grahic Jump Location
Fig. 1

Chemical structure of curcumin: (1E,6E)-1,7-bis (4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; molecular formula C21H20O6; molar mass 368.38 g/mol; melting point 183 °C (361 K); and exhibit keto-enol tautomerism and the enol form is more energetically stable in the solid phase and in solution ∼95%

Grahic Jump Location
Fig. 2

(a) Ordinary suspension and (b) the nanosuspension of curcumin

Grahic Jump Location
Fig. 3

(a) PCS and (b) LD particles size distribution of curcumin formulations

Grahic Jump Location
Fig. 4

Curcumin nanocrystal-loaded capsules (a) and marketed capsules (b)

Grahic Jump Location
Fig. 5

Projected health benefits of Cur-500

Grahic Jump Location
Fig. 6

Percentage of dissolved curcumin from nanocrystal-loaded capsules (formulation A) compared to microcrystal-loaded capsules (formulation B) in water (a); buffer at pH 1.2 (b), and pH 6.8 (c)

Grahic Jump Location
Fig. 7

Percentage of dissolved curcumin from nanocrystals-loaded capsule in comparison with marketed capsule in water (a); buffer at pH 1.2 (b), and pH 6.8 (c)

Grahic Jump Location
Fig. 8

Transfer of microcrystals to nanocrystals leads to an increase in surface area (upper). Increase in saturation solubility cs, decrease in diffusional distance h and increase in the concentration gradient cs − cx/h. All effects increase the dissolution velocity dc/dt.

Grahic Jump Location
Fig. 9

Mechanism of action: finely dispersed nanocrystals versus aggregated nanocrystals




Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In